Open AccessUtilization of Direct Oral Anticoagulants in People Living with Human Immunodeficiency Virus: Observational Data from the District of Columbia Cohort
Author(s) -
Jomy George,
Safia Kuriakose,
Anne Monroe,
Qi Hou,
Morgan Byrne,
Alice Pau,
Henry Masur,
Colleen Hadigan,
Amanda D. Castel,
Michael A. Horberg
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa284
Subject(s) - medicine , rivaroxaban , cohort , anticoagulant , warfarin , cohort study , medical prescription , pediatrics , pharmacology , atrial fibrillation
Direct oral anticoagulants (DOACs) have become first-line treatment for venous thrombotic events. DOAC prescribing trends among people living with human immunodeficiency virus (PWH) are not well described. The coadministration of DOACs with the antiretroviral (ARV) pharmacokinetic boosters ritonavir (RTV) or cobicistat (COBI) may be complicated by pharmacokinetic interactions.